Clinical trials
Phase 2 Breast Neoplasms trials in Singapore
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
42 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2004 | 3 |
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 4 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 1 |
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 5 |
| 2016 | 2 |
| 2017 | 4 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 20 |
| Unknown status | 11 |
| Terminated | 6 |
| Active, not recruiting | 2 |
| Recruiting | 2 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National University Hospital, Singapore | 12 |
| National Cancer Centre, Singapore | 5 |
| GlaxoSmithKline | 4 |
| Bayer | 3 |
| Novartis Pharmaceuticals | 3 |
| Genentech, Inc. | 2 |
| Hoffmann-La Roche | 2 |
| Puma Biotechnology, Inc. | 2 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2 |
| ALX Oncology Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Breast Neoplasms | 42 |
| Carcinoma, Non-Small-Cell Lung | 4 |
| Neoplasm Metastasis | 4 |
| Colorectal Neoplasms | 2 |
| Melanoma | 2 |
| Neoplasms | 2 |
| Salivary Gland Neoplasms | 2 |
| Sarcoma | 2 |
| Anxiety Disorders | 1 |
| Biliary Tract Neoplasms | 1 |
Trials
Showing 1 to 25 of 42. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.